10x Genomics, Inc.
Every calculator, already run for TXG
Open the full toolkit →You have the numbers on TXG. Get the argument.
A written report on which of these readings actually decide the outcome for 10x Genomics, Inc., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
19 analysts covering TXGAnalyst Price Target Disagreement for 10x Genomics, Inc.
Wall Street's bull case implies -4% from the current price; the bear case implies -57%. A 53% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
Insider Trading Activity for TXG
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About 10x Genomics, Inc.
10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific. The company offers Chromium platform, a single cell portfolio that enables analysis of individual biological components, as well as includes microfluidic chips and related consumables, Chromium X Series, and Chromium instruments; and QuantumScale single cell RNA and single cell methylation kits. It also provides Visium platform, a spatial analysis platform that uses high density DNA arrays to encode the physical location of biological analytes within a sample. This pl…
TXG — frequently asked
Is TXG a buy right now?
Wall Street's consensus rating on 10x Genomics, Inc. is Buy across 19 analysts, with a mean price target of $62.13 (-34% vs. the current $93.50). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
Is TXG overvalued?
TXG trades at — trailing earnings, against a DCF fair value of $16 per share. The current price implies 33% annual free-cash-flow growth for a decade. Open the DCF or reverse-DCF tool to change the assumptions and see the range.
When is TXG's next earnings date?
10x Genomics, Inc. is next scheduled to report earnings around Nov 5, 2026. A full TXG research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
What is the analyst price target disagreement for 10x Genomics, Inc.?
Analysts covering 10x Genomics, Inc. (TXG) range from a bear-case target of $40.00 to a bull-case high of $90.00, with a mean consensus target of $62.13 across 15 analysts. The spread of $50.00 (53% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare 10x Genomics, Inc. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For 10x Genomics, Inc.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full TXG research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on 10x Genomics, Inc., in minutes. 3 free reports included with every account — no credit card required.